Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR).
about
Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophreniaSecond-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of lifeLong-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia: pragmatic versus explanatory study designsAdherence and rehospitalizations in patients with schizophrenia: evidence from Japanese claims data.Definitions and drivers of relapse in patients with schizophrenia: a systematic literature reviewAssessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study resultsLong acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR databaseA one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America.Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial.Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysisEfficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophreniaLong acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory.Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database.Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in JapanA retrospective observational study of the effectiveness of paliperidone palmitate on acute inpatient hospitalization ratesHolistic Consideration of Patients with Schizophrenia to Improve Medication Adherence and Outcomes.Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons.Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece.Enhancing adherence, subjective well-being and quality of life in patients with schizophrenia: which role for long-acting risperidone?Nurses' perceptions of medication adherence in schizophrenia: results of the ADHES cross-sectional questionnaire survey.Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia.Association between adherence to and persistence with atypical antipsychotics and psychiatric relapse among US Medicaid-enrolled patients with schizophrenia.Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.Psychiatrists' awareness of partial and nonadherence to antipsychotic medication in schizophrenia: results from an Asia-Pacific surveyAssociation between Medication Adherence and Duration of Outpatient Treatment in Patients with SchizophreniaPsychiatrists' perceptions of the clinical importance, assessment and management of patient functioning in schizophrenia in Europe, the Middle East and Africa.Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional studyRisperidone long-acting injection in the treatment of schizophrenia: 24-month results from the electronic Schizophrenia Treatment Adherence Registry in Canada.Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review.Effects of controlled-release formulations of atypical antipsychotics on functioning and quality of life of schizophrenic individuals.Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective.Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia.Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment.Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands.A further consideration on long-acting injectable versus oral antipsychotics in the treatment of schizophrenia: a narrative review and critical appraisal.Health care resource utilization and costs of California Medicaid patients with schizophrenia treated with paliperidone palmitate once monthly or atypical oral antipsychotic treatment.
P2860
Q24597701-CF6AB799-12A7-4019-B95A-5A4544C99EB2Q26752965-67B25563-7C47-472C-8EAC-77C0DACDDDA0Q28085407-06C4BC20-3E4D-4AFE-BD12-927C0C446525Q30937746-067B07E1-95AF-452F-8E9D-004372069483Q33589087-DE1012E2-6122-4638-9E2A-25DA4E8994BDQ34048194-06304AFD-7E80-453E-AAA1-FB29876A7A63Q34208127-5E515860-2EB9-4485-A615-B30429654596Q34210712-34B09F0B-5A82-4A7C-849B-26A22304730BQ34315836-B3D78C24-DAD5-4A89-8F2B-CFDA7F17035FQ34418847-1EEB1912-10D4-4F24-B082-94569EED141EQ34560335-BB25555E-9334-438A-A148-3F835FF435D5Q34660553-AC545600-2477-42A9-B5F1-3CB4A34B626AQ34982167-F3D8D929-4515-4B31-B1ED-6CD5579A5D00Q35186007-A46D68A0-9D20-41A8-B129-6B0D68925669Q35211261-D0FD5DE6-1BF9-4E90-A0F5-56749D488ADCQ35249595-51255D60-E060-4F84-9F2A-F979F7A4E6B1Q35659829-2C4B1AAD-862A-4FF5-AF7E-4DB48592D2D6Q35688404-0684E0F3-B98F-4161-B51B-2F90B3B0C2CCQ35965617-1DBD2705-0F52-44C4-A381-57F37316DB1BQ35971060-4AAFB8FD-FA03-448E-B119-BE1AEF87CCA3Q36198389-86543AC3-3C7D-4CDA-862D-BBAA64B82DDBQ36211694-D85403A4-3500-4449-981A-9101EECCBE79Q36489412-C1E50631-73EE-41C8-9AD7-3B5CCB169FA8Q36597061-9B0E0F6F-7585-4AB6-AC86-FBE12F9B37FCQ36670942-6A0088AB-BAA4-4CF2-A658-9619B1895841Q36698856-4A6E84AB-5BA7-45CC-9B3D-50F129176174Q37104411-39D62060-6CE1-425A-B695-BA6589751A5CQ37136984-006F8E22-5845-4ACD-ADFC-13CED101F9E7Q37187202-6A03F983-D99F-477C-8A12-99724D4F30C1Q37547469-F5413144-49FD-4D59-866F-434B8D0FF79AQ37616971-3925E62D-ED10-4497-8040-55410CCF9E29Q37778398-C1201214-335C-400E-AFD0-3CBF0145F447Q38010780-0CC72835-D914-4922-B4F9-A6DA7B1365ADQ38115487-9D02EFB0-0825-43F9-B436-61995B6CB358Q38206231-9D64359A-04D9-409F-B73A-9F1F79E7CB70Q38473914-0E7614DD-5E51-47FC-9F4D-8EE1D664F831Q38475985-CEE5D7D2-25AF-429A-B8D8-0998D2E1C342Q38649630-E7CDE376-35F0-434F-8080-4EA05EFAF217Q38659006-51574FF0-1FEA-453D-AA3B-9103A16DE780Q39043536-8E476F1C-E6BE-482F-977B-5E668CE4470C
P2860
Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR).
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Long-term outcomes in patients ...... t Adherence Registry (e-STAR).
@en
Long-term outcomes in patients ...... a Treatment Adherence Registry
@nl
type
label
Long-term outcomes in patients ...... t Adherence Registry (e-STAR).
@en
Long-term outcomes in patients ...... a Treatment Adherence Registry
@nl
prefLabel
Long-term outcomes in patients ...... t Adherence Registry (e-STAR).
@en
Long-term outcomes in patients ...... a Treatment Adherence Registry
@nl
P2093
P1433
P1476
Long-term outcomes in patients ...... nt Adherence Registry (e-STAR)
@en
P2093
A Bordallo Aragón
A Carrillo Gómez
A Casas Losada
A Clar Forteza
A Delgado Martel
A Escudero Nafs
A Fernández Benítez
A Fernández Pellicer
A Franco Bonet
A García López
P304
P356
10.1016/J.EURPSY.2008.12.002
P407
P577
2009-02-04T00:00:00Z